吉利德科学宣布收购Tubulis公司,此举将为公司带来潜在同类最优的抗体偶联药物以及新一代技术平台,从而显著增强其在肿瘤治疗领域的产品管线布局。
吉利德科学宣布收购Tubulis公司,此举将为公司带来潜在同类最优的抗体偶联药物以及新一代技术平台,从而显著增强其在肿瘤治疗领域的产品管线布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.